UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...

Phosphoinositide 3-Kinase Regulates Glycolysis through Mobilization of Aldolase from the Actin Cytoskeleton

Cell, 2016-01, Vol.164 (3), p.433-446

2016

Link zum Volltext

Verfügbarkeit prüfen

Phosphoinositide 3-kinase inhibitors induce DNA damage through nucleoside depletion

Proceedings of the National Academy of Sciences - PNAS, 2016-07, Vol.113 (30), p.E4338-E4347

2016

Link zum Volltext

Verfügbarkeit prüfen

Inhibition of cytokine signaling by ruxolitinib and implications for COVID-19 treatment

Clinical immunology (Orlando, Fla.), 2020-09, Vol.218, p.108517-108517, Article 108517

2020

Link zum Volltext

Verfügbarkeit prüfen

Itacitinib (INCB039110), a JAK1 Inhibitor, Reduces Cytokines Associated with Cytokine Release Syndrome Induced by CAR T-cell Therapy

Clinical cancer research, 2020-12, Vol.26 (23), p.6299-6309

2020

Link zum Volltext

Verfügbarkeit prüfen

Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer

Cancer discovery, 2012-11, Vol.2 (11), p.1048-1063

2012

Link zum Volltext

Verfügbarkeit prüfen

Ruxolitinib, a JAK1/JAK2 Selective Inhibitor, Ameliorates Gastrointestinal and Cutaneous Pathogenesis in MHC-Mismatched Preclinical Models of Acute and Chronic Graft-Versus-Host Disease

Blood, 2019-11, Vol.134 (Supplement_1), p.5608-5608

2019

Link zum Volltext

Verfügbarkeit prüfen

Itacitinib, a JAK1 Selective Inhibitor Preserves Graft-Versus-Leukemia (GVL), Enhances Survival and Is Highly Efficacious in a MHC-Mismatched Mouse Model of Acute GvHD

Blood, 2018-11, Vol.132 (Supplement 1), p.4522-4522

2018

Link zum Volltext

Verfügbarkeit prüfen

Ruxolitinib, a JAK1/JAK2 Selective Inhibitor Is Highly Efficacious in Corticosteroid Untreated and Refractory MHC-Mismatched Mouse Model of Acute GvHD

Blood, 2018-11, Vol.132 (Supplement 1), p.4523-4523

2018

Link zum Volltext

Verfügbarkeit prüfen

Preclinical characterization of itacitinib (INCB039110), a novel selective inhibitor of JAK1, for the treatment of inflammatory diseases

European journal of pharmacology, 2020-10, Vol.885, p.173505-173505, Article 173505

2020

Link zum Volltext

Verfügbarkeit prüfen

Abstract 1876: INCB052793, a JAK1 selective inhibitor, is highly efficacious in PDX and xenograft models of acute myeloid leukemia (AML) expressing elevated endogenous pSTAT3/pSTAT5

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.1876-1876

2018

Link zum Volltext

Verfügbarkeit prüfen

Abstract IA08: PI3K- and PARP-inhibitors for the treatment of women cancers

Clinical cancer research, 2016-01, Vol.22 (2_Supplement), p.IA08-IA08

2016

Link zum Volltext

Verfügbarkeit prüfen

Bortezomib induces nuclear translocation of IκBα resulting in gene-specific suppression of NF-κB--dependent transcription and induction of apoptosis in CTCL

Molecular cancer research, 2011-02, Vol.9 (2), p.183-194

2011

Link zum Volltext

Verfügbarkeit prüfen

Ruxolitinib, a JAK1/JAK2 selective inhibitor, ameliorates acute and chronic steroid-refractory GvHD mouse models

Immunotherapy, 2021-08, Vol.13 (12), p.977

2021

Link zum Volltext

Verfügbarkeit prüfen

Gene-specific repression of proinflammatory cytokines in stimulated human macrophages by nuclear IκBα

The Journal of immunology (1950), 2010-09, Vol.185 (6), p.3685-3693

2010

Link zum Volltext

Verfügbarkeit prüfen

Abstract 159: Analysis of resistance to the combination of a PI3K- and Parp-inhibitor using a genomic sequencing approach

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.159-159

2016

Link zum Volltext

Verfügbarkeit prüfen

Closing escape routes: inhibition of IL-8 signaling enhances the anti-tumor efficacy of PI3K inhibitors

Breast cancer research : BCR, 2013-04, Vol.15 (2), p.308-308, Article 308

2013

Link zum Volltext

Verfügbarkeit prüfen

Abstract 1081: Non-random genomic alterations in BRCA1-related breast cancer

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.1081-1081

2015

Link zum Volltext

Verfügbarkeit prüfen

Abstract 2032: Combination of epigenetic regulation via LSD1 inhibition with signal transduction inhibitors significantly enhances anti-tumor activity in models of hematologic malignancies

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.2032-2032

2017

Link zum Volltext

Verfügbarkeit prüfen

Abstract 2650: PI 3-Kinase inhibitors enhance the synthetic lethality of Parp inhibitors

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.2650-2650

2015

Link zum Volltext

Verfügbarkeit prüfen

Abstract 4781: EBV infection of mammary epithelial cells promotes malignant transformation

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8_Supplement), p.4781-4781

2013

Link zum Volltext

Verfügbarkeit prüfen

Abstract 2300: Brain penetrant CDK4/6 inhibitor PRT3645 demonstrates anti-tumor activity and enhances survival in glioblastoma and breast cancer brain metastasis models

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.2300-2300

2022

Link zum Volltext

Verfügbarkeit prüfen

Abstract 1234: The novel FGFR4-selective inhibitor INCB062079 is efficacious in models of hepatocellular carcinoma harboring FGF19 amplification

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.1234-1234

2017

Link zum Volltext

Verfügbarkeit prüfen

Abstract IA21: Combination treatments that include PI3K-inhibitors for the treatment of triple-negative breast cancer

Molecular cancer therapeutics, 2015-07, Vol.14 (7_Supplement), p.IA21-IA21

2015

Link zum Volltext

Verfügbarkeit prüfen

Abstract 5973: The brain penetrant CDK4/6 Inhibitor, PRT3645, is highly effective in combination with other targeted therapies in preclinical models of NSCLC, CRC, and HER2-positive breast cancer

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7_Supplement), p.5973-5973

2023

Link zum Volltext

Verfügbarkeit prüfen

Abstract CT338: Combination of a PI3K- and a PARP-inhibitor to treat high-grade serous ovarian or triple-negative breast cancer

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.CT338-CT338

2014

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 82

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(75)
Mit Volltextzugriff
(78)

Publikationsform

Sprache

Englisch
(82)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Phosphoinositide 3-Kinase Regulates Glycolysis through Mobilization of Aldolase from the Actin Cytoskeleton

Phosphoinositide 3-kinase inhibitors induce DNA damage through nucleoside depletion

Inhibition of cytokine signaling by ruxolitinib and implications for COVID-19 treatment

Itacitinib (INCB039110), a JAK1 Inhibitor, Reduces Cytokines Associated with Cytokine Release Syndrome Induced by CAR T-cell Therapy

Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer

Ruxolitinib, a JAK1/JAK2 Selective Inhibitor, Ameliorates Gastrointestinal and Cutaneous Pathogenesis in MHC-Mismatched Preclinical Models of Acute and Chronic Graft-Versus-Host Disease

Itacitinib, a JAK1 Selective Inhibitor Preserves Graft-Versus-Leukemia (GVL), Enhances Survival and Is Highly Efficacious in a MHC-Mismatched Mouse Model of Acute GvHD

Ruxolitinib, a JAK1/JAK2 Selective Inhibitor Is Highly Efficacious in Corticosteroid Untreated and Refractory MHC-Mismatched Mouse Model of Acute GvHD

Preclinical characterization of itacitinib (INCB039110), a novel selective inhibitor of JAK1, for the treatment of inflammatory diseases

Abstract 1876: INCB052793, a JAK1 selective inhibitor, is highly efficacious in PDX and xenograft models of acute myeloid leukemia (AML) expressing elevated endogenous pSTAT3/pSTAT5

Abstract IA08: PI3K- and PARP-inhibitors for the treatment of women cancers

Bortezomib induces nuclear translocation of IκBα resulting in gene-specific suppression of NF-κB--dependent transcription and induction of apoptosis in CTCL

Ruxolitinib, a JAK1/JAK2 selective inhibitor, ameliorates acute and chronic steroid-refractory GvHD mouse models

Gene-specific repression of proinflammatory cytokines in stimulated human macrophages by nuclear IκBα

Abstract 159: Analysis of resistance to the combination of a PI3K- and Parp-inhibitor using a genomic sequencing approach

Closing escape routes: inhibition of IL-8 signaling enhances the anti-tumor efficacy of PI3K inhibitors

Abstract 1081: Non-random genomic alterations in BRCA1-related breast cancer

Abstract 2032: Combination of epigenetic regulation via LSD1 inhibition with signal transduction inhibitors significantly enhances anti-tumor activity in models of hematologic malignancies

Abstract 2650: PI 3-Kinase inhibitors enhance the synthetic lethality of Parp inhibitors

Abstract 4781: EBV infection of mammary epithelial cells promotes malignant transformation

Abstract 2300: Brain penetrant CDK4/6 inhibitor PRT3645 demonstrates anti-tumor activity and enhances survival in glioblastoma and breast cancer brain metastasis models

Abstract 1234: The novel FGFR4-selective inhibitor INCB062079 is efficacious in models of hepatocellular carcinoma harboring FGF19 amplification

Abstract IA21: Combination treatments that include PI3K-inhibitors for the treatment of triple-negative breast cancer

Abstract 5973: The brain penetrant CDK4/6 Inhibitor, PRT3645, is highly effective in combination with other targeted therapies in preclinical models of NSCLC, CRC, and HER2-positive breast cancer

Abstract CT338: Combination of a PI3K- and a PARP-inhibitor to treat high-grade serous ovarian or triple-negative breast cancer

Suchergebnisse filtern